Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Pfizer’s $10 billion licensing deal with Innovent, alongside rising U.S. debate over expanding COINS Act restrictions on China biotech investment, signals a structural shift in global pharma strategy. The announcement, combined with Astellas’ Xtandi patent cliff response and ASCO scrutiny
As development timelines shrink across the pharmaceutical industry, companies are placing greater emphasis on speed, scalability and manufacturing certainty. The trend, highlighted at CPHI Japan 2026, signals mounting pressure on drugmakers and CDMOs to deliver faster without compromising GMP compliance,
FDA launches one-day inspections and expands AI systems Elsa 4.0 and HALO at its headquarters in the United States, introducing a major shift in global pharmaceutical regulation. The move accelerates risk-based oversight and structured-data review, reshaping GMP expectations for manufacturers
At ASCO 2026 in Chicago, ASCO 2026, Wondercel Therapeutics, founder Frank Fan, also the inventor of Carvykti, presented early clinical and manufacturing data on a novel allogeneic CAR-T cell therapy platform called Revo-U. The approach aims to overcome key GMP
Idea Pharma’s 2026 Global Innovation and Invention Index, released this week, shows a clear shift in global pharma leadership. Eli Lilly takes the top position in both innovation and invention, while Pfizer continues to decline after its post-COVID peak. The
A recent industry analysis by Loong Wang, fact-checked by Zachary Zubulake, highlights how quantum chemistry, pharmaceutical AI, and GPU-accelerated computing are converging to solve key limitations in drug discovery. The report shows that inconsistent experimental data and poor model interpretability
Bristol Myers Squibb has expanded its collaboration with Anthropic to deploy the Claude AI system across multiple pharmaceutical functions, including research, manufacturing, quality monitoring, and regulatory workflows. The move reflects a broader industry shift toward AI-driven operations, but experts warn
The United States Food and Drug Administration (FDA) has launched a pilot program to enable real-time clinical trial data review, allowing safety signals and endpoints to reach regulators as data is recorded. In a discussion with Pharmaceutical Executive, Dr. Richard
Emerging biopharma companies are rapidly adopting agentic AI to automate workflows and connect decision-making across regulated environments. Industry discussions involving ZS and SynOx Therapeutics highlight this accelerating shift. However, experts warn that many organizations still lack validated infrastructure, strong data
Big pharmaceutical companies are accelerating a shift toward highly specialized R&D strategies as they prepare for a wave of patent expirations and rising pricing pressure. In a PharmaVoice report published on May 20, 2026, industry leaders including, AstraZeneca and Roche,